Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | IARS1 | P41252 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30552158 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL199059 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL28599405 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL29087496 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL1685517 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL13482942 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| SCHEMBL199058 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2777940 | 0.98 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29087500 | 0.98 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4277313 | 0.98 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| EP-3036305-B1 | COMPOUNDS WITH TERMINAL HETEROARYLCYANOVINYLENE GROUPS AND THEIR USE IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | CRBN, PDCD11, CD47 | DPP4 3828/4885DPP8 3422/4885DPP9 2919/4885 |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | CRBN, PDCD11, CD47 | DPP4 3594/4885DPP8 3181/4885DPP9 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.